MedTrace Logo

Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.

NCT02582424 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2016-01-26

No results posted yet for this study

Summary

This will be an 8 week multicenter, randomized, double-blind, placebo controlled trial.

Conditions

Interventions

OTHER

PD-L0101

92% EPA+6 mg ATX+50 mg TCT GG BID

OTHER

placebo

placebo

Sponsors & Collaborators

  • Primus Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jay Udani, MD · Medicus Research 18250 Roscoe Blvd. Northridge CA 91325

  • Andrea Lawless, MD · Provident Clinical Research 211 E Lake St. Addison IL 60101

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-08-31
Completion
2013-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582424 on ClinicalTrials.gov